

Aerosolized Antibiotics for Treating Ventilator-associated Pneumonia

Essay

*Submitted for partial fulfillment of master degree in intensive
care medicine*

By

Maged Gamal Ahmed
M. B., B. Ch

Supervised by

Prof. Mostafa Kamel Fouad

*Professor of Anesthesia, Intensive Care Medicine and pain Management
Faculty of Medicine- Ain Shams University*

Assist. Prof. Karim Youssef Kamal

*Assistant Professor of Anesthesia, Intensive Care Medicine and pain
Management
Faculty of Medicine- Ain Shams University*

Dr. Ahmed Abdel Dayem Abdul Haq

*Lecturer of Anesthesia, Intensive Care Medicine and pain Management
Faculty of Medicine- Ain Shams University*

**Faculty of Medicine
Ain Shams University
2016**

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

﴿وَقُلْ رَبِّ زِدْنِي عِلْمًا﴾

سورة طه الآية رقم ١١٤



Acknowledgement

First and foremost, thanks to **Allah** the Almighty to whom I relate any success in achieving any work in my life.

I would like to express my very great appreciation to **Prof. Dr. Mostafa Kamel Fouad**, Professor of Anesthesia, Intensive Care and pain management, for his precious instructions, expert supervision and valuable comments during the course of this work.

I would like to offer my special thanks and deep appreciation to **Prof. Dr. Karim Youssef Kamal**, Assistant Professor of Anesthesia, Intensive Care and pain management, for his help and valuable advice throughout the performance of this work.

I would also like to thank **Dr. Ahmed Abdel Dayem Abdul Haq**, Lecturer of Anesthesia, Intensive Care and pain management, for providing me with very valuable and constructive suggestions, for his support and enthusiastic encouragement.

Last but not least, sincere gratitude to **My Family** for their continuous encouragement and spiritual support.



Maged Gamal Ahmed

Contents

	Page
List of Abbreviations	i
List of Tables	iii
List of Figures	iv
Introduction	1
Aim of the work	3
Pathogenesis of VAP.....	4
Diagnostic Strategies and Approaches of VAP.....	24
Prevention of VAP.....	31
Treatment of VAP and the role of aerosolized antibiotics in treatment.....	67
Summary.....	87
References.....	117
Arabic summary.....	--

List of Abbreviations

A. baumannii	:	Acinetobacter baumannii
ARDS	:	Acute respiratory distress syndrome
ASA	:	American Society of Anesthesiologists
BAL	:	Broncho alveolar lavage
CDC	:	Centers for Disease Control
CMS	:	Colistimethate sodium
COPD	:	Chronic obstructive pulmonary disease
CPIS	:	Clinical pulmonary infection score
CRP	:	C-reactive protein
DVT	:	Deep venous thrombosis
EF	:	Elastin fiber
ETT	:	Endotracheal tube
FDA	:	Food and Drug Administration
H.influenzae	:	Haemophilus influenzae
HAP	:	Hospital acquired pneumonia
HMEs	:	Heat-and-moisture exchangers
HSV	:	Herpes simplex virus
ICP	:	Infection control practitioner
ICU	:	Intensive care unit
IHI	:	Institute of healthcare improvement
ISIBTS	:	Isotonic saline instillation before tracheal suctioning
MDR	:	Multiple drug resistance
MIC	:	Minimum inhibitory concentration
MRSA	:	Methicillin-resistant Staphylococcus aureus
MS	:	Mucus shaver
MSSA	:	Methicillin-sensitive Staphylococcus aureus

List of Abbreviations (Cont.)

NIV	:	Noninvasive mechanical ventilation
NP	:	Nosocomial pneumonia
NSQIP	:	National Surgical Quality Improvement Program
P. aeruginosa	:	Pseudomonase aeruginosa
Pc	:	Intracuff pressure
PCT	:	Pro-calcitonin
PEEP	:	Positive end expiratory pressure
PSB	:	Protected specimen brushing
PSS	:	Patient Safety in Surgery
RF	:	Respiratory failure
S. aureus	:	Staphylococcus aureus
S. pneumonia	:	Streptococcus pneumoniae
SDD	:	Selective decontamination of the digestive tract
sTREM	:	Soluble triggering receptor expressed on myeloid cells
USA	:	United State of America
VAP	:	Ventilator associated pneumonia

List of Tables

<i>Table</i>	<i>Title</i>	<i>Page</i>
1	Known and suspected microbiological causes of VAP.	14
2	Risk factors for multidrug resistant pathogens (MDR) in VAP.	20
3	Clinical criteria used in diagnosing ventilator-associated pneumonia	27
4	Respiratory failure risk index	45
5	Respiratory risk index score	46
6	Initial empiric antibiotic therapy for hospital acquired pneumonia or ventilator associated pneumonia in patients with no known risk factors for multidrug-resistant pathogens, any disease severity and early onset	68
7	Empiric antibiotic treatment in patients with known risk factors for MDR pathogens	72

List of Figures

<i>Fig.</i>	<i>Title</i>	<i>Page</i>
1	Routes of colonization/infection in mechanically ventilated patients	7
2	Prevention measures of ventilator-associated pneumonia	31
3	Mucus shaver endotracheal tube	47
4	Hi-Lo Evac tube	50
5	Management of ventilator associated pneumonia in patients at risk for methicillin resistant <i>Staphylococcus aureus</i>	71

Introduction

Pneumonia can be generally defined as inflammation of the lung parenchyma, in which consolidation of the affected part and a filling of the alveolar air spaces with exudates, inflammatory cells and fibrin is characteristic **(Baltimore, 2003)**.

The placement of an endotracheal tube increases the risk of developing ventilator-associated pneumonia (VAP) by 6-20 fold compared to critically ill patients who are not intubated **(Niederman et al., 2005)**.

Development of ventilator-associated pneumonia (VAP) is undoubtedly associated with significant morbidity and mortality rates that range from 5.8% to 27% **(Valles et al., 2007)**.

Traditionally administered intravenous antibiotics do not reach a bactericidal concentration in the tissue of lungs: intravenously administered antibiotics are primarily detected in respiratory segments of lungs, but not in sputum **(Hoiby, 2011) (Moroz et al., 2007)**. Also complicating this therapy is a significantly increased rate of antimicrobial resistance in recent years giving further limiting treatment options **(Nicasio et al., 2008)**.

Aerosol antibiotics administration offers the theoretical advantages of achieving high drug concentrations at the infection site and low systemic absorption **(Dhand, 2007)**, it have been shown to be useful adjuncts to systemic antibiotic therapy for reducing morbidity and mortality due to VAP **(Luyt et al., 2009)**.

In addition, aerosolized antibiotics typically have minimal systemic absorption, which can decrease the risk of adverse drug events such as nephrotoxicity with aminoglycosides and colistimethate compared with intravenous therapy (**Wood et al., 2007**).

Recent studies have indicated that aerosolized aminoglycosides and colistin may be safe and effective for the treatment of VAP caused by *P. aeruginosa* or *A. baumannii* (**Mohr et al., 2007**), (**Michalopoulos et al., 2008**).

Aim of the work

The Aim of this work is to discuss the management of ventilator-associated pneumonia and the role of aerosolized antibiotics as adjunctive to systemic antibiotics in the treatment of patients with VAP.

Ventilator Associated Pneumonia (VAP)

Definitions

Nosocomial pneumonia or hospital acquired pneumonia is defined as an infection of the lung parenchyma that was neither present nor incubating at the time of hospital admission (**Fishman, 2008**).

Mechanical ventilation is an essential feature of modern intensive care unit (ICU) care. Unfortunately, mechanical ventilation is associated with a substantial risk of ventilator-associated pneumonia (VAP). VAP is the most common nosocomial infection in the ICU (**Bouadmaa et al., 2012**).

The incidence of VAP ranging from 9% to 40%, and is associated with prolonged hospitalization, increased health care costs, and a 15-45% attributable mortality (**Safdar et al., 2005**).

VAP is defined as subtype of nosocomial pneumonia developing in mechanically ventilated patients within 48hrs or more after intubation, with an endotracheal tube or tracheostomy tube with no clinical evidence suggesting the presence or probable development of pneumonia at the time of initial intubation. Based on differences in causes, VAP has been divided into early (≤ 96 hrs of admission) and late onset (> 96 hrs of admission) (**Fishman, 2008**).

Incidence

In a systematic review of 38 prospective cohort and nonrandomized studies including approximately 48000

mechanically ventilated patients, the incidence of ventilator-associated pneumonia varied from 10 to 20% with twice the mortality of similar patients without VAP. The crude mortality for VAP has ranged from 13 to 70%, but most investigators have reported rates in the range of 20 to 40% (**Fishman, 2008**).

In the United States of America, VAP has recently been proposed as a quality-of-care indicator for hospitals because it is generally believed that VAP increases both morbidity and mortality of ICU patients (**Klompas and Platt, 2007**).

This belief is predominantly based on the results of observational studies, using a (matched) cohort design. However, a systematic approach to combine quantitatively the results of all available studies evaluated the association between the development of VAP and mortality does not exist (**Melsen et al., 2009**).

Pathogenesis of VAP

Understanding the pathogenesis of VAP is essential to devising strategies for prevention of these infections. Advances in the understanding of pathogenesis have led to the development of specific measures that can greatly reduce the risk of VAP (**Tablan et al., 2004**).

Defense Mechanisms for Prevention of Respiratory Infection in the Normal Host

The major defense mechanisms in the normal host include anatomic airway barriers, cough reflexes, mucus, and mucociliary clearance. The ciliated mucosa of the upper respiratory tract has a major role in removing particulate

matter and microbes that have gained access to the bronchial tree. Composition of airway secretions, an effective mucociliary reflex, and an effective cough below the terminal bronchioles, the cellular and humoral immune systems are essential components of host defense. Alveolar macrophages and leukocytes remove particulate matter as well as potential pathogens, elaborate cytokines that activate the systemic cellular immune response, and act as antigen-presenting cells to the humoral arm of immunity. Immunoglobulin and Complement inactivate and opsonize bacteria and bacterial products within the respiratory tract facilitate phagocytosis (**Strieter et al., 2003**).

▫*In the mechanically ventilated patient:*

A number of factors conspire to compromise host defenses: critical illness, comorbidities, and malnutrition impair the immune system, and, most importantly, endotracheal intubation thwarts the cough reflex, compromises mucociliary clearance, injures the tracheal epithelial surface, and provides a direct conduit for rapid access of bacteria from above into the lower respiratory tract (**Safdar et al., 2005**).

It would probably be more accurate pathogenetically to rename VAP as “Endotracheal-intubation-related pneumonia.” Invasive devices and procedures and antimicrobial therapy create a favorable milieu for antimicrobial-resistant nosocomial pathogens to colonize the aerodigestive tract (**Safdar and Maki, 2004**). This combination of impaired host defenses and continuous exposure of the lower respiratory tract to large numbers of potential pathogens through the endotracheal tube (ETT)

puts the mechanically ventilated patient at great jeopardy of developing VAP (Safdar et al., 2005).




Fig.(1): Routes of colonization/infection in mechanically ventilated patients. Colonization of the aerodigestive tract may occur endogenously (A and B) or exogenously (C through F). Exogenous colonization may result in primary colonization of the oropharynx or may be the result of direct inoculation into the lower respiratory tract during manipulations of respiratory equipment (D), during using of respiratory devices (E), or from contaminated aerosols (F) (Safdar et al., 2005).

Oropharyngeal Colonization

The normal flora of the oropharynx in the non intubated patient without critical illness is composed predominantly of viridians streptococci, Haemophilus